Recruiting studies: Ebv Infection After Allogenic Hsct

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infec
Phase 1/Phase 2 · 1 location(s) · LucasBio · NCT07670468 Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT06119256 Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Chil
NA · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07693881 TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04013802 Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Phase 3 · 33 location(s) · Tobias Feuchtinger · NCT04832607 Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06393985 Donor-Derived Viral Specific T-cells (VSTs)
Phase 1/Phase 2 · 3 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02048332 The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults
Phase 2 · 24 location(s) · Pediatric Transplantation & Cellular Therapy Consortium · NCT03509961 Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/Phase 2 · 1 location(s) · Daihong Liu · NCT07368634 A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative
Phase 3 · 71 location(s) · Pierre Fabre Medicament · NCT03394365 A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of He
Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT02007356 Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cel
NA · 1 location(s) · Peking University People's Hospital · NCT06581081 Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infe
NA · 1 location(s) · LucasBio · NCT07685457 Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05805605 Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A
NA · 1 location(s) · Beijing Children's Hospital · NCT07488728

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.